Fleming, M. T., Pond, G. R., Armstrong, A. J., Wood, B. A., Brookes, M., Leopold, L. H., … Sonpavde, G. (2011). Ability of serum alkaline phosphatase (ALP) changes to complement PSA changes and predict survival in men with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel and prednisone (DP). Journal of Clinical Oncology, 29(15_suppl), e15019–e15019. https://doi.org/10.1200/jco.2011.29.15_suppl.e15019

Fleming, M. T., G. R. Pond, A. J. Armstrong, B. A. Wood, M. Brookes, L. H. Leopold, V. B. Matveev, J. M. Burke, J. R. Caton, and G. Sonpavde. “Ability of serum alkaline phosphatase (ALP) changes to complement PSA changes and predict survival in men with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel and prednisone (DP).” Journal of Clinical Oncology 29, no. 15_suppl (May 20, 2011): e15019–e15019. https://doi.org/10.1200/jco.2011.29.15_suppl.e15019.

Fleming MT, Pond GR, Armstrong AJ, Wood BA, Brookes M, Leopold LH, et al. Ability of serum alkaline phosphatase (ALP) changes to complement PSA changes and predict survival in men with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel and prednisone (DP). Journal of Clinical Oncology. 2011 May 20;29(15_suppl):e15019–e15019.

Fleming, M. T., et al. “Ability of serum alkaline phosphatase (ALP) changes to complement PSA changes and predict survival in men with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel and prednisone (DP).” Journal of Clinical Oncology, vol. 29, no. 15_suppl, American Society of Clinical Oncology (ASCO), May 2011, pp. e15019–e15019. Crossref, doi:10.1200/jco.2011.29.15_suppl.e15019.

Fleming MT, Pond GR, Armstrong AJ, Wood BA, Brookes M, Leopold LH, Matveev VB, Burke JM, Caton JR, Sonpavde G. Ability of serum alkaline phosphatase (ALP) changes to complement PSA changes and predict survival in men with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel and prednisone (DP). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011 May 20;29(15_suppl):e15019–e15019.